Life Sciences Spotlight: Chinese regulatory enforcement action showing no signs of slowing down; and more

Since our last edition, there has been a number of developments in the life sciences sector across the Asia-Pacific region and we are pleased to be able to update you on these recent trends.

It is evident that the focus on compliance in the region will continue for some time unabated and changes to the regulatory landscape are continuous and increasing. Those in the industry who have responsibility for legal and compliance have an ever-increasing burden in this respect. Not only are the goal posts continually shifting but there are many, many more hurdles that need to be cleared. In short, ensuring compliance is getting much more difficult.

In this issue

  • Chinese regulatory enforcement action showing no signs of slowing down
  • Patent strategies and loyalty discounts
  • Data privacy protection in new PRC consumer rights law effective from 15 March 2014
  • Enforcing compliance — how to ensure that employees in Australia comply with regulatory codes
  • China’s simplified merger review is effective
  • Australian New Zealand therapeutic products agency — will we ever get there?
  • M&As, manufacturing and distributing medical devices in Japan

Click on the link below to read the rest of the DLA Piper briefing.

Briefings from DLA Piper

View more briefings from DLA Piper

Analysis from The Lawyer

View more analysis from The Lawyer


3 Noble Street

Turnover (£m): 1,539.00
No. of lawyers: 4,374(UK 200)
Jurisdiction: Global
No. of offices: Over 75
No. of qualified lawyers: 625 (International 50)